Panacea surges on inking pact with TDB for financial assistance for Dengue Tetravalent Vaccine

15 Nov 2017 Evaluate

Panacea Biotec is currently trading at Rs. 258.90, up by 27.80 points or 12.03% from its previous closing of Rs. 231.10 on the BSE.

The scrip opened at Rs. 238.90 and has touched a high and low of Rs. 271.90 and Rs. 236.15 respectively. So far 1,76,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 275.90 on 24-Oct-2017 and a 52 week low of Rs. 103.00 on 21-Nov-2016.

Last one week high and low of the scrip stood at Rs. 271.90 and Rs. 219.75 respectively. The current market cap of the company is Rs. 1,580.27 crore.

The promoters holding in the company stood at 74.60%, while Institutions and Non-Institutions held 0.91% and 24.49% respectively.

Panacea Biotec has signed agreement with Technology Development Board (TDB), Govt. of India for providing the financial assistance of Rs 28.99 crore for the Development and commercialization of Dengue Tetravalent Vaccine (Live Attenuated, Recombinant, Lyophilized).

Moreover, the company’s collaboration with National Institutes of Health (NIH), USA has led to the development of an advanced Dengue Vaccine in India with proven safety in pre-clinical studies. According to the results from clinical trials conducted by NIH, the candidate Dengue vaccine has been found to stimulate a strong immune response against all 4 serotypes in all age-groups and expected to be a single dose vaccine. Panacea Biotec has obtained Phase I/II clinical trial permission from Drug Controller General of India, New Delhi. Clinical trial lots production is in advanced stages at Panacea Biotec’s cGMP facility and clinical trials will be started by early 2018.

Currently some of the vaccine candidates under development elsewhere require 2-3 doses to achieve desired immune response, while the published clinical data of only licensed vaccine outside India has shown a poor immune response against Type-2 strain of Dengue besides being a 3 dose vaccine and protects only the age group of 9-45 yrs.

Panacea Biotec is a leading biotechnology company with established research, manufacturing and marketing capabilities. It is one of the largest vaccine producers and leading Biotechnology Companies in India.


Panacea Biotec Share Price

326.95 -17.70 (-5.14%)
08-Dec-2025 15:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1790.05
Dr. Reddys Lab 1272.70
Cipla 1498.90
Zydus Lifesciences 920.90
Lupin 2061.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×